董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nicholas Robbins Cherry | 男 | Chief Financial Officer, Director | 49 | 17.26万英镑 | 未持股 | 2018-12-31 |
| Rolf Stahel | 男 | Non-Executive Chairman of the Board of Director | 74 | 9.50万英镑 | 未持股 | 2018-12-31 |
| Sijmen de Vries | 男 | Non-Executive Director | 59 | 3.04万英镑 | 未持股 | 2018-12-31 |
| Craig Cook | 男 | Chief Executive Officer, Director | 52 | 25.02万英镑 | 未持股 | 2018-12-31 |
| Huaizheng Peng | 男 | Non-Executive Director | 55 | 3.04万英镑 | 未持股 | 2018-12-31 |
| Simon Turton | 男 | Senior Independent Non-Executive Director | 51 | 3.80万英镑 | 未持股 | 2018-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nicholas Robbins Cherry | 男 | Chief Financial Officer, Director | 49 | 17.26万英镑 | 未持股 | 2018-12-31 |
| Craig Cook | 男 | Chief Executive Officer, Director | 52 | 25.02万英镑 | 未持股 | 2018-12-31 |
董事简历
中英对照 | 中文 | 英文- Nicholas Robbins Cherry
-
Nicholas Robbins Cherry，他曾一直担任Midatech公司的财务董事，包括任职Midatech公司的前任实体（2014年2月以来）。他于2014年9月12日入选Midatech公司的董事会。加入Midatech公司之前，他曾担任The Marketing Practice Limited公司的财务董事（从2013年1月到2014年1月）。此前，他曾担任多种职务，最近担任CACI Limited公司的财务董事（从2008年2月到2013年1月）。他是注册会计师，持有工商管理硕士学位和药理学学士学位。
Nicholas Robbins Cherry has served as our Chief Financial Officer including his service to our predecessor entity since February 2014. Mr. Robbins-Cherry was appointed to our Board of Directors on September 12 2014. Prior to joining Midatech, Mr. Robbins-Cherry served as the Finance Director of The Marketing Practice Limited from January 2013 to January 2014. Prior to that, he served in various positions, most recently as the Finance Director, of CACI Limited from February 2008 to January 2013. Mr. Robbins-Cherry is a chartered accountant and has a Master’s of Business Administration and Bachelors of Science in Pharmacology. - Nicholas Robbins Cherry，他曾一直担任Midatech公司的财务董事，包括任职Midatech公司的前任实体（2014年2月以来）。他于2014年9月12日入选Midatech公司的董事会。加入Midatech公司之前，他曾担任The Marketing Practice Limited公司的财务董事（从2013年1月到2014年1月）。此前，他曾担任多种职务，最近担任CACI Limited公司的财务董事（从2008年2月到2013年1月）。他是注册会计师，持有工商管理硕士学位和药理学学士学位。
- Nicholas Robbins Cherry has served as our Chief Financial Officer including his service to our predecessor entity since February 2014. Mr. Robbins-Cherry was appointed to our Board of Directors on September 12 2014. Prior to joining Midatech, Mr. Robbins-Cherry served as the Finance Director of The Marketing Practice Limited from January 2013 to January 2014. Prior to that, he served in various positions, most recently as the Finance Director, of CACI Limited from February 2008 to January 2013. Mr. Robbins-Cherry is a chartered accountant and has a Master’s of Business Administration and Bachelors of Science in Pharmacology.
- Rolf Stahel
-
Rolf Stahel，他曾一直担任 Midatech公司的董事会非执行主席兼董事，包括任职 Midatech公司的前身实体（2014年3月1日以来）。2009年以来，他曾一直担任Connexios Sciences公司的非执行主席兼董事。2014年4月以来，他曾担任Ergomed Group plc （AIM：ERGO）的非执行主席兼董事。他也是Chesyl Pharma公司的唯一股东兼创始人（从1994年3月到2003年3月）。他曾担任Shire Pharmaceuticals Group公司（NASDAQ：SHPG）公司的首席执行官兼董事。此前，他曾担任多种职务27年，任职于Wellcome公司（GlaxoSmithKline公司的前身公司，NYSE：GSK）。他此前曾担任非执行主席，任职于EUSA、Cosmos Pharmaceuticals SpA （SIX：COPN）、PowderMed Ltd.、Newron Pharmaceuticals SpA （SWX：NWRN）。
Rolf Stahel has served as our Non-Executive Chairman of the Board and director including his service to our predecessor entity since March 1 2014. Since December 2016 Mr. Stahel served as the Non-Executive Chairman and a director of Ampha Limited. Between 2009 and 2016 Mr. Stahel served as the Non-Executive Chairman and a director of Connexios Sciences Pvt. Ltd., and between April 2014 and March 2017 he served as Non-Executive Chairman and a director of Ergomed Group plc AIM: ERGO. Mr. Stahel is also the sole shareholder and founder of Chesyl Pharma Ltd. from March 1994 to March 2003 Mr. Stahel served as the Chief Executive Officer and a director of Shire Pharmaceuticals Group plc (NASDAQ: SHPG). Prior to that time, Mr. Stahel worked in various positions with Wellcome plc, the predecessor to GlaxoSmithKline plc (NYSE: GSK), for 27 years. Mr. Stahel has previously served as the Non-Executive Chairman of EUSA, Cosmos Pharmaceuticals SpA (SIX: COPN), PowderMed Ltd. and Newron Pharmaceuticals SpA (SWX: NWRN). - Rolf Stahel，他曾一直担任 Midatech公司的董事会非执行主席兼董事，包括任职 Midatech公司的前身实体（2014年3月1日以来）。2009年以来，他曾一直担任Connexios Sciences公司的非执行主席兼董事。2014年4月以来，他曾担任Ergomed Group plc （AIM：ERGO）的非执行主席兼董事。他也是Chesyl Pharma公司的唯一股东兼创始人（从1994年3月到2003年3月）。他曾担任Shire Pharmaceuticals Group公司（NASDAQ：SHPG）公司的首席执行官兼董事。此前，他曾担任多种职务27年，任职于Wellcome公司（GlaxoSmithKline公司的前身公司，NYSE：GSK）。他此前曾担任非执行主席，任职于EUSA、Cosmos Pharmaceuticals SpA （SIX：COPN）、PowderMed Ltd.、Newron Pharmaceuticals SpA （SWX：NWRN）。
- Rolf Stahel has served as our Non-Executive Chairman of the Board and director including his service to our predecessor entity since March 1 2014. Since December 2016 Mr. Stahel served as the Non-Executive Chairman and a director of Ampha Limited. Between 2009 and 2016 Mr. Stahel served as the Non-Executive Chairman and a director of Connexios Sciences Pvt. Ltd., and between April 2014 and March 2017 he served as Non-Executive Chairman and a director of Ergomed Group plc AIM: ERGO. Mr. Stahel is also the sole shareholder and founder of Chesyl Pharma Ltd. from March 1994 to March 2003 Mr. Stahel served as the Chief Executive Officer and a director of Shire Pharmaceuticals Group plc (NASDAQ: SHPG). Prior to that time, Mr. Stahel worked in various positions with Wellcome plc, the predecessor to GlaxoSmithKline plc (NYSE: GSK), for 27 years. Mr. Stahel has previously served as the Non-Executive Chairman of EUSA, Cosmos Pharmaceuticals SpA (SIX: COPN), PowderMed Ltd. and Newron Pharmaceuticals SpA (SWX: NWRN).
- Sijmen de Vries
-
Sijmen de Vries，他曾一直担任 Midatech公司的董事会的非执行成员（2004年10月以来），包括任职Midatech公司的前任实体。他曾担任Pharming Group NV （Euronext：PHARM） 的首席执行官（2008年11月以来）。此前，他曾担任4-Antibody公司和Morphochem AG的首席执行官。此前，他曾任职Novartis Pharma公司、Novartis Ophthalmics公司、SmithKline Beecham Pharmaceuticals公司，在那里他曾担任高级业务商业职务。他持有the University of Amsterdam的医学博士学位，以及Ashridge Management College（位于英国）的综合管理方面的工商管理硕士学位。
Sijmen de Vries has been our Chief Executive Officer since 2008 and he has also served in the capacity of interim Chief Financial Officer from May 2020 through November 16 2020 upon the commencement of Mr. Wakkerman’s tenure as Chief Financial Officer. Prior to joining Pharming, Dr. De Vries was the CEO of 4-Antibody and Morphochem AG. Dr. De Vries also held senior business and commercial positions at Novartis, Novartis Ophthalmics and at SmithKline Beecham Pharmaceuticals plc. Dr. De Vries holds an MD degree from the University of Amsterdam and an MBA in General Management from Ashridge Management College UK. Dr. De Vries is also a non-executive director of Midatech Pharma plc. - Sijmen de Vries，他曾一直担任 Midatech公司的董事会的非执行成员（2004年10月以来），包括任职Midatech公司的前任实体。他曾担任Pharming Group NV （Euronext：PHARM） 的首席执行官（2008年11月以来）。此前，他曾担任4-Antibody公司和Morphochem AG的首席执行官。此前，他曾任职Novartis Pharma公司、Novartis Ophthalmics公司、SmithKline Beecham Pharmaceuticals公司，在那里他曾担任高级业务商业职务。他持有the University of Amsterdam的医学博士学位，以及Ashridge Management College（位于英国）的综合管理方面的工商管理硕士学位。
- Sijmen de Vries has been our Chief Executive Officer since 2008 and he has also served in the capacity of interim Chief Financial Officer from May 2020 through November 16 2020 upon the commencement of Mr. Wakkerman’s tenure as Chief Financial Officer. Prior to joining Pharming, Dr. De Vries was the CEO of 4-Antibody and Morphochem AG. Dr. De Vries also held senior business and commercial positions at Novartis, Novartis Ophthalmics and at SmithKline Beecham Pharmaceuticals plc. Dr. De Vries holds an MD degree from the University of Amsterdam and an MBA in General Management from Ashridge Management College UK. Dr. De Vries is also a non-executive director of Midatech Pharma plc.
- Craig Cook
-
Craig Cook，他曾一直担任Midatech公司的首席运营官兼首席医疗官，包括任职Midatech公司的前任实体（2014年1月以来）。从2011年11月到2014年5月，他曾担任Sedation Solutions公司的合伙人。从2005年5月到2013年12月，他曾担任Spacecode Technologies公司（他于2005年共同创立的公司）首席执行官。他此前曾担任执行职务，任职于Eli Lilly and Company （NYSE：LLY）、Novartis International AG （NYSE：NVS）、Johnson and Johnson （NYSE：JNJ）、Serono Biotech公司。他也是Swisscare Health的英国住宅保健集团的创始人。他也曾担任Ippon Capital SA的生命科学实践的首席顾问。他是一名合格的医生，拥有药理科学学士学位、麻醉学文凭和工商管理硕士学位。
Craig Cook has served as our Chief Executive Officer and member of our Board of Directors since June 1 2018. Prior to that, Dr. Cook served as our Chief Operating Officer and Chief Medical Officer including our predecessor entity since January 2014. From May 2005 to December 2013 Dr. Cook served as Chief Executive Officer of Spacecode Technologies, which he co-founded in 2005. In addition, from November 2011 to May 2014 he served as a partner at Sedation Solutions. Dr. Cook has previously held positions at Eli Lilly and Company NYSE: LLY, Novartis International AG (NYSE: NVS), Johnson and Johnson (NYSE: JNJ) and Serono Biotech. He is also a founder of Swisscare Health residential care group in the United Kingdom. Dr. Cook was also a lead advisor for Ippon Capital SA’s life sciences practice. Dr. Cook is a qualified physician and has a Bachelor’s of Science in pharmacology, a diploma in anesthesiology and a Masters of Business Administration. - Craig Cook，他曾一直担任Midatech公司的首席运营官兼首席医疗官，包括任职Midatech公司的前任实体（2014年1月以来）。从2011年11月到2014年5月，他曾担任Sedation Solutions公司的合伙人。从2005年5月到2013年12月，他曾担任Spacecode Technologies公司（他于2005年共同创立的公司）首席执行官。他此前曾担任执行职务，任职于Eli Lilly and Company （NYSE：LLY）、Novartis International AG （NYSE：NVS）、Johnson and Johnson （NYSE：JNJ）、Serono Biotech公司。他也是Swisscare Health的英国住宅保健集团的创始人。他也曾担任Ippon Capital SA的生命科学实践的首席顾问。他是一名合格的医生，拥有药理科学学士学位、麻醉学文凭和工商管理硕士学位。
- Craig Cook has served as our Chief Executive Officer and member of our Board of Directors since June 1 2018. Prior to that, Dr. Cook served as our Chief Operating Officer and Chief Medical Officer including our predecessor entity since January 2014. From May 2005 to December 2013 Dr. Cook served as Chief Executive Officer of Spacecode Technologies, which he co-founded in 2005. In addition, from November 2011 to May 2014 he served as a partner at Sedation Solutions. Dr. Cook has previously held positions at Eli Lilly and Company NYSE: LLY, Novartis International AG (NYSE: NVS), Johnson and Johnson (NYSE: JNJ) and Serono Biotech. He is also a founder of Swisscare Health residential care group in the United Kingdom. Dr. Cook was also a lead advisor for Ippon Capital SA’s life sciences practice. Dr. Cook is a qualified physician and has a Bachelor’s of Science in pharmacology, a diploma in anesthesiology and a Masters of Business Administration.
- Huaizheng Peng
-
Huaizheng Peng自2019年2月起担任董事会非执行成员。彭博士目前担任CMS HK:867的国际运营总经理，自2011年以来一直担任该职位，并担任CMS子公司A&B HK的首席执行官。在加入CMS之前，彭博士是私募股权公司Northland Bancorp的合伙人，在此之前，他是投资银行和股票经纪人Seymour Pierce的生命科学主管和企业融资董事。他目前担任Neurelis，Inc.、Destiny Pharma plc（LON:DEST）、Blueberry Therapeutics Limited、Acticor Biopharma、Helius Medical Technologies（NASDAQ:HSDT，TSX:HSM）和Cambridge United China Collaborations Limited以及多家CMS子公司的非执行董事。彭博士在中国湖南医学院获得医学学士学位和硕士学位，并在伦敦大学医学院获得分子病理学博士学位。
Huaizheng Peng has served as a non-executive member of our Board of Directors since February 2019. Dr. Peng currently serves as the General Manager of International Operations at CMS HK:867 where has served in such capacity since 2011 and the Chief Executive Officer of A&B HK, a subsidiary of CMS. Prior to joining CMS, Dr. Peng was a partner at Northland Bancorp, a private equity firm, and before that he was head of life sciences and a director of corporate finance at Seymour Pierce, an investment bank and stockbroker. He currently serves as a non-executive director of Neurelis, Inc., Destiny Pharma plc (LON: DEST), Blueberry Therapeutics Limited, Acticor Biopharma, Helius Medical Technologies (NASDAQ: HSDT, TSX: HSM) and Cambridge United China Collaborations Limited, as well as a number of CMS subsidiaries. Dr. Peng received a Bachelor’s degree and a Master’s degree in medicine from Hunan Medical College, China, and a Ph.D. in molecular pathology from University College London Medical School. - Huaizheng Peng自2019年2月起担任董事会非执行成员。彭博士目前担任CMS HK:867的国际运营总经理，自2011年以来一直担任该职位，并担任CMS子公司A&B HK的首席执行官。在加入CMS之前，彭博士是私募股权公司Northland Bancorp的合伙人，在此之前，他是投资银行和股票经纪人Seymour Pierce的生命科学主管和企业融资董事。他目前担任Neurelis，Inc.、Destiny Pharma plc（LON:DEST）、Blueberry Therapeutics Limited、Acticor Biopharma、Helius Medical Technologies（NASDAQ:HSDT，TSX:HSM）和Cambridge United China Collaborations Limited以及多家CMS子公司的非执行董事。彭博士在中国湖南医学院获得医学学士学位和硕士学位，并在伦敦大学医学院获得分子病理学博士学位。
- Huaizheng Peng has served as a non-executive member of our Board of Directors since February 2019. Dr. Peng currently serves as the General Manager of International Operations at CMS HK:867 where has served in such capacity since 2011 and the Chief Executive Officer of A&B HK, a subsidiary of CMS. Prior to joining CMS, Dr. Peng was a partner at Northland Bancorp, a private equity firm, and before that he was head of life sciences and a director of corporate finance at Seymour Pierce, an investment bank and stockbroker. He currently serves as a non-executive director of Neurelis, Inc., Destiny Pharma plc (LON: DEST), Blueberry Therapeutics Limited, Acticor Biopharma, Helius Medical Technologies (NASDAQ: HSDT, TSX: HSM) and Cambridge United China Collaborations Limited, as well as a number of CMS subsidiaries. Dr. Peng received a Bachelor’s degree and a Master’s degree in medicine from Hunan Medical College, China, and a Ph.D. in molecular pathology from University College London Medical School.
- Simon Turton
-
Simon Turton，2014年12月起，担任Midatech的非执行董事。他从2014年3月起，担任的董事长，直到2014年12月它们被Midatech收购。2015年1月起，他担任Gensmile Limited的总经理。2002年，他加入，最后的职务是欧洲地区医疗保健行业投资业务总监，直到2011年6月。他曾担任Archimedes Pharma、Eurand、ProStrakan Group plc 、Tornier, Inc.（NASDAQ： TRNX）的董事。他在INSEAD获得工商管理硕士学位，在University of London获得药剂学博士学位。
Simon Turton has served as a non-executive member of our Board of Director since December 2014. Dr. Turton served as Chairman of Q Chip and OpsiRx Pharmaceuticals from March 2014 until their acquisition by Midatech in December 2014. Since January 2015 he has served as the Managing Director of Gensmile Limited. In 2002 Dr. Turton joined Warburg Pincus’, most recently as head of healthcare investing activities in Europe, until June 2011. Dr. Turton has previously served on the board of Archimedes Pharma, Eurand, ProStrakan Group plc and Tornier, Inc. NASDAQ: TRNX. Dr. Turton has a Master’s of Business Administration from INSEAD and a Ph.D. in pharmacy from the University of London. - Simon Turton，2014年12月起，担任Midatech的非执行董事。他从2014年3月起，担任的董事长，直到2014年12月它们被Midatech收购。2015年1月起，他担任Gensmile Limited的总经理。2002年，他加入，最后的职务是欧洲地区医疗保健行业投资业务总监，直到2011年6月。他曾担任Archimedes Pharma、Eurand、ProStrakan Group plc 、Tornier, Inc.（NASDAQ： TRNX）的董事。他在INSEAD获得工商管理硕士学位，在University of London获得药剂学博士学位。
- Simon Turton has served as a non-executive member of our Board of Director since December 2014. Dr. Turton served as Chairman of Q Chip and OpsiRx Pharmaceuticals from March 2014 until their acquisition by Midatech in December 2014. Since January 2015 he has served as the Managing Director of Gensmile Limited. In 2002 Dr. Turton joined Warburg Pincus’, most recently as head of healthcare investing activities in Europe, until June 2011. Dr. Turton has previously served on the board of Archimedes Pharma, Eurand, ProStrakan Group plc and Tornier, Inc. NASDAQ: TRNX. Dr. Turton has a Master’s of Business Administration from INSEAD and a Ph.D. in pharmacy from the University of London.
高管简历
中英对照 | 中文 | 英文- Nicholas Robbins Cherry
Nicholas Robbins Cherry，他曾一直担任Midatech公司的财务董事，包括任职Midatech公司的前任实体（2014年2月以来）。他于2014年9月12日入选Midatech公司的董事会。加入Midatech公司之前，他曾担任The Marketing Practice Limited公司的财务董事（从2013年1月到2014年1月）。此前，他曾担任多种职务，最近担任CACI Limited公司的财务董事（从2008年2月到2013年1月）。他是注册会计师，持有工商管理硕士学位和药理学学士学位。
Nicholas Robbins Cherry has served as our Chief Financial Officer including his service to our predecessor entity since February 2014. Mr. Robbins-Cherry was appointed to our Board of Directors on September 12 2014. Prior to joining Midatech, Mr. Robbins-Cherry served as the Finance Director of The Marketing Practice Limited from January 2013 to January 2014. Prior to that, he served in various positions, most recently as the Finance Director, of CACI Limited from February 2008 to January 2013. Mr. Robbins-Cherry is a chartered accountant and has a Master’s of Business Administration and Bachelors of Science in Pharmacology.- Nicholas Robbins Cherry，他曾一直担任Midatech公司的财务董事，包括任职Midatech公司的前任实体（2014年2月以来）。他于2014年9月12日入选Midatech公司的董事会。加入Midatech公司之前，他曾担任The Marketing Practice Limited公司的财务董事（从2013年1月到2014年1月）。此前，他曾担任多种职务，最近担任CACI Limited公司的财务董事（从2008年2月到2013年1月）。他是注册会计师，持有工商管理硕士学位和药理学学士学位。
- Nicholas Robbins Cherry has served as our Chief Financial Officer including his service to our predecessor entity since February 2014. Mr. Robbins-Cherry was appointed to our Board of Directors on September 12 2014. Prior to joining Midatech, Mr. Robbins-Cherry served as the Finance Director of The Marketing Practice Limited from January 2013 to January 2014. Prior to that, he served in various positions, most recently as the Finance Director, of CACI Limited from February 2008 to January 2013. Mr. Robbins-Cherry is a chartered accountant and has a Master’s of Business Administration and Bachelors of Science in Pharmacology.
- Craig Cook
Craig Cook，他曾一直担任Midatech公司的首席运营官兼首席医疗官，包括任职Midatech公司的前任实体（2014年1月以来）。从2011年11月到2014年5月，他曾担任Sedation Solutions公司的合伙人。从2005年5月到2013年12月，他曾担任Spacecode Technologies公司（他于2005年共同创立的公司）首席执行官。他此前曾担任执行职务，任职于Eli Lilly and Company （NYSE：LLY）、Novartis International AG （NYSE：NVS）、Johnson and Johnson （NYSE：JNJ）、Serono Biotech公司。他也是Swisscare Health的英国住宅保健集团的创始人。他也曾担任Ippon Capital SA的生命科学实践的首席顾问。他是一名合格的医生，拥有药理科学学士学位、麻醉学文凭和工商管理硕士学位。
Craig Cook has served as our Chief Executive Officer and member of our Board of Directors since June 1 2018. Prior to that, Dr. Cook served as our Chief Operating Officer and Chief Medical Officer including our predecessor entity since January 2014. From May 2005 to December 2013 Dr. Cook served as Chief Executive Officer of Spacecode Technologies, which he co-founded in 2005. In addition, from November 2011 to May 2014 he served as a partner at Sedation Solutions. Dr. Cook has previously held positions at Eli Lilly and Company NYSE: LLY, Novartis International AG (NYSE: NVS), Johnson and Johnson (NYSE: JNJ) and Serono Biotech. He is also a founder of Swisscare Health residential care group in the United Kingdom. Dr. Cook was also a lead advisor for Ippon Capital SA’s life sciences practice. Dr. Cook is a qualified physician and has a Bachelor’s of Science in pharmacology, a diploma in anesthesiology and a Masters of Business Administration.- Craig Cook，他曾一直担任Midatech公司的首席运营官兼首席医疗官，包括任职Midatech公司的前任实体（2014年1月以来）。从2011年11月到2014年5月，他曾担任Sedation Solutions公司的合伙人。从2005年5月到2013年12月，他曾担任Spacecode Technologies公司（他于2005年共同创立的公司）首席执行官。他此前曾担任执行职务，任职于Eli Lilly and Company （NYSE：LLY）、Novartis International AG （NYSE：NVS）、Johnson and Johnson （NYSE：JNJ）、Serono Biotech公司。他也是Swisscare Health的英国住宅保健集团的创始人。他也曾担任Ippon Capital SA的生命科学实践的首席顾问。他是一名合格的医生，拥有药理科学学士学位、麻醉学文凭和工商管理硕士学位。
- Craig Cook has served as our Chief Executive Officer and member of our Board of Directors since June 1 2018. Prior to that, Dr. Cook served as our Chief Operating Officer and Chief Medical Officer including our predecessor entity since January 2014. From May 2005 to December 2013 Dr. Cook served as Chief Executive Officer of Spacecode Technologies, which he co-founded in 2005. In addition, from November 2011 to May 2014 he served as a partner at Sedation Solutions. Dr. Cook has previously held positions at Eli Lilly and Company NYSE: LLY, Novartis International AG (NYSE: NVS), Johnson and Johnson (NYSE: JNJ) and Serono Biotech. He is also a founder of Swisscare Health residential care group in the United Kingdom. Dr. Cook was also a lead advisor for Ippon Capital SA’s life sciences practice. Dr. Cook is a qualified physician and has a Bachelor’s of Science in pharmacology, a diploma in anesthesiology and a Masters of Business Administration.